Mosapride as a Pre-Endoscopy Preparation in a Patient Receiving GLP-1 Receptor Agonist Therapy

Area of Science:

• Gastroenterology
• Endocrinology
• Pharmacology

Background:

• Long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes management.
• GLP-1RAs are known to cause delayed gastric emptying, potentially complicating upper gastrointestinal procedures.
• Significant gastric residue can impair mucosal visualization during endoscopy.

Purpose of the Study:

• To report a case of successful gastric clearance using mosapride in a patient experiencing delayed gastric emptying due to GLP-1RA therapy.
• To evaluate the efficacy of mosapride as a pre-endoscopic preparation in this clinical scenario.

Main Methods:

• A 66-year-old male patient with type 2 diabetes on a long-acting GLP-1RA presented with significant gastric residue prior to upper GI endoscopy.
• Standard fasting protocols were insufficient to clear the gastric contents.
• Mosapride citrate, a gastroprokinetic agent, was administered three days before the scheduled endoscopy.

Main Results:

• Administration of mosapride resulted in complete gastric clearance.
• Optimal mucosal visualization was achieved during the upper GI endoscopy.
• The patient tolerated mosapride without adverse events.

Conclusions:

• Mosapride may be an effective therapeutic option to manage GLP-1RA-induced delayed gastric emptying.
• This approach can facilitate successful upper gastrointestinal endoscopy in patients treated with GLP-1RAs.
• Further studies are warranted to confirm the efficacy and safety of mosapride in this context.